|
Re: Continued Roth coverage imo points to a Nasdaq listing....
|
5
|
Resverlogix Corp.
|
May 02, 2019 10:45AM
|
|
Re: Rebuys start at $2.28
|
5
|
Resverlogix Corp.
|
Aug 09, 2018 05:46PM
|
|
Novartis Phase III study shows Canakinumab reduces MACE events
|
5
|
Resverlogix Corp.
|
Jun 22, 2017 11:19AM
|
|
Re: Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
|
5
|
Resverlogix Corp.
|
Sep 14, 2017 10:45AM
|
|
Re: Riding the Xtandi coat tails
|
5
|
Zenith Epigenetics
|
Jul 17, 2018 02:38PM
|
|
Re: 3 point MACE vs 5 point MACE
|
5
|
Resverlogix Corp.
|
Nov 02, 2018 01:17PM
|
|
Re: Breakthrough Therapy Designation Application
|
5
|
Resverlogix Corp.
|
Dec 06, 2019 09:37AM
|
|
Re: Statistical Considerations
|
5
|
Resverlogix Corp.
|
Mar 07, 2018 06:20PM
|
|
Re: Que sera sera....
|
5
|
Resverlogix Corp.
|
Apr 03, 2018 07:02PM
|
|
Re: RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
|
5
|
Resverlogix Corp.
|
Jan 24, 2018 09:41PM
|
|
Re: BIO-Europe Presentation
|
5
|
Zenith Epigenetics
|
Mar 21, 2018 11:37AM
|
|
Compilation of BET inhibitor Trials
|
5
|
Zenith Epigenetics
|
Oct 05, 2017 01:21PM
|
|
Re: https://scr.zacks.co...
|
5
|
Zenith Epigenetics
|
May 04, 2020 11:39AM
|
|
Re: I'm glad the SSRA issue has finally been put to bed....
|
5
|
Resverlogix Corp.
|
Sep 19, 2018 07:04AM
|
|
Re: Another RVX-208 Poster at IAS 2015 May 26
|
5
|
Resverlogix Corp.
|
May 22, 2015 10:51AM
|
|
Re: AD Link
|
5
|
Resverlogix Corp.
|
Jun 27, 2019 11:51PM
|
|
Upcoming Resverlogix and Zenith Events
|
5
|
Resverlogix Corp.
|
Jan 12, 2016 03:31PM
|
|
Kudos to Dr. Kausik Ray
|
5
|
Resverlogix Corp.
|
Mar 13, 2019 07:27PM
|
|
Re: We might already be at 125 events....
|
5
|
Resverlogix Corp.
|
Oct 25, 2017 01:04PM
|
|
Re: BIO Investor Forum, Oct 22-23
|
5
|
Resverlogix Corp.
|
Oct 23, 2019 10:56AM
|
